Indiana is part of a multi-state settlement involving a global pharmaceutical company. The agreement with insulin manufacturer Novo Nordisk settles allegations that the company did not comply with Food and Drug Administration requirements regarding the potential risk of a rare form of cancer in people who use one of its Type II diabetes medications.
As part of the settlement, the federal government will receive more than $43 million, with state Medicaid programs receiving $3.3 million. Indiana Medicaid will receive $155,000.
Novo Nordisk was accused of not complying with the FDA’s required Risk Evaluation and Mitigation Strategies for the medication Victoza. The settlement resolves six lawsuits involving private parties filing suit on behalf of federal and state governments. The suits accused the company of submitting false claims from 2010 to 2014 to federal health care programs by giving a misleading impression about the potential risk involving the use of Victoza.